Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Moodys

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR PAROXETINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Paroxetine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000368 ↗ Treatment of Panic Disorder: Long Term Strategies Completed National Institute of Mental Health (NIMH) Phase 3 1999-02-01 Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.
NCT00000368 ↗ Treatment of Panic Disorder: Long Term Strategies Completed New York State Psychiatric Institute Phase 3 1999-02-01 Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.
NCT00012558 ↗ Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Completed National Institute of Mental Health (NIMH) N/A 1998-09-01 A long-term study of current treatments for bipolar disorder, including medications and psychosocial therapies.
NCT00018733 ↗ Biological Aspects of Depression and Antidepressant Drugs Completed US Department of Veterans Affairs N/A 1996-09-01 This study will be measuring changes in depressive symptoms over a 7 week time period. Double-blind placebo controlled trial using the pharmacologic agents Paroxetine or Desipramine.
NCT00018733 ↗ Biological Aspects of Depression and Antidepressant Drugs Completed VA Office of Research and Development N/A 1996-09-01 This study will be measuring changes in depressive symptoms over a 7 week time period. Double-blind placebo controlled trial using the pharmacologic agents Paroxetine or Desipramine.
NCT00018759 ↗ Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients Completed SmithKline Beecham Phase 4 2001-03-01 This study aims to determine if treatment with an SSRI antidepressant medication, paroxetine, is associated with cellular calcium response to serotonin, platelet serotonin receptors, and improvement in mood in depressed patients with or without hypertension. It is hypothesized that platelets of hypertensive patients with depressive symptomatology with be hyper-responsive to serotonin. Additionally, treatment with an SSRI antidepressant is expected to produce a down-regulation of the serotonin receptor with an associated reduction in platelet cytosolic calcium response as well as improved mood.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Paroxetine

Condition Name

Condition Name for Paroxetine
Intervention Trials
Depression 25
Major Depressive Disorder 24
Depressive Disorder 19
Healthy 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Paroxetine
Intervention Trials
Depression 91
Disease 81
Depressive Disorder 78
Depressive Disorder, Major 52
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Paroxetine

Trials by Country

Trials by Country for Paroxetine
Location Trials
United States 499
Canada 42
Germany 31
China 30
Japan 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Paroxetine
Location Trials
New York 33
California 31
Pennsylvania 28
Texas 23
Florida 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Paroxetine

Clinical Trial Phase

Clinical Trial Phase for Paroxetine
Clinical Trial Phase Trials
Phase 4 73
Phase 3 53
Phase 2/Phase 3 5
[disabled in preview] 72
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Paroxetine
Clinical Trial Phase Trials
Completed 187
Unknown status 19
Terminated 18
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Paroxetine

Sponsor Name

Sponsor Name for Paroxetine
Sponsor Trials
GlaxoSmithKline 53
National Institute of Mental Health (NIMH) 17
Sanofi 12
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Paroxetine
Sponsor Trials
Other 215
Industry 140
U.S. Fed 35
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Johnson and Johnson
Colorcon
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.